Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleRandomised controlled trial of cannabis based medicinal extracts (CBME) in central neuropathic pain due to multiple sclerosis.
Author(s) Young CA, Rog DJ
Journal, Volume, IssueIV. Congress of the European Federation of IASP Chapters (EFIC), September 2-6 2003, Prague
Major outcome(s)Significant reduction in pain
IndicationMultiple sclerosis;PainAbstract

Background: Central neuropathic pain can be an intractable problem for some multiple sclerosis (MS) patients.
Aim: To evaluate the efficacy and safety of THC:CBD CBME in the relief of central neuropathic pain due to MS, using the Neuropathic Pain Scale (NPS) and single Box Scale-11 (BS-11) pain severity score.
Methods: A 5-week (1 week run-in, 4 week treatment), randomised, double-blinded, placebo-controlled, parallel group trial in 66 MS patients was conducted.
The study medication was an oro-mucosal preparation of a whole plant extract which delivered 2.7mg of THC and 2.5mg CBD per spray. Patients were allowed to self-titrate up to a maximum of 48 sprays per day.
Results: Sixty-four patients (96.9%) completed the trial (n=32 CBME, n=32 placebo).
Efficacy: Significant mean reductions in pain were observed at Week 4 for CBME compared to placebo, using both BS-11 score (p=0.005) and Neuropathic Pain Scale (NPS) scores (p=0.039).
A statistically significant reduction in sleep disturbance using a 0-10 scale (p=0.003), and a greater overall impression of change (p=0.005) in favour of CBME was observed.
Safety: Thirty patients (88.2%) on CBME and 22 (68.8%) on placebo had at least one adverse event; however only 1 patient (CBME) withdrew from the study.
There was a small, but statistically significant mean difference between treatments in the long term storage component of the Selective Reminding Test, in favour of placebo (p = 0.009).
Conclusion: CBME showed significant reductions in both neuropathic pain and pain-related sleep disturbance in patients with MS. CBMEs appear well tolerated by most patients.

Dose(s)up to 130 mg per day
Duration (days)28
Participants66 multiple sclerosis patients
DesignControlled study
Type of publicationMeeting abstract
Address of author(s)The Walton Centre for Neurology & Neurosurgery, Liverpool, UK
Full text

[Back to Overview]  [IACM Homepage]